Professor Ogawa, Mr. Echigo (PhD student), and their colleagues in Kanazawa University report in Eur J Nucl Med Mol Imaging that combination of an At-211-labeled agent with immune checkpoint blockade significantly enhances its therapeutic effect. This strategy represents a promising advancement in the development of next-generation cancer therapies that combine targeted alpha therapy and immunotherapy.

POSTECH & ImmunoBiome identify gut–immune–brain axis as key driver beyond genetics.

SRPX2 is a chondroitin sulfate proteoglycan (CSPG) exhibiting significant N-glycosylation, which influences its conformation, interactions, and functions, as evidenced by the enhanced glycosylation and functional impact of the N327S mutation. It plays versatile roles in multiple diseases. SRPX2 promotes cancer progression (e.g., gastric, pancreatic, thyroid, glioblastoma) by enhancing proliferation, migration, invasion, and chemoresistance via pathways like TGF-β, PI3K/AKT, Wnt/β-catenin, and FAK/SRC/ERK, correlating with poor prognosis. SRPX2 also plays critical roles in neurodevelopment; mutations are linked to language disorders, autism spectrum disorder (ASD), and potentially Rolandic epilepsy (though evidence is complex and may involve interactions like GRIN2A). SRPX2, a protein characterized by sushi repeat domains, plays a crucial role in synaptogenesis and modulates complement-mediated synaptic pruning processes. Additionally, SRPX2 contributes to idiopathic pulmonary fibrosis via TGF-β signaling, angiogenesis via μPAR/integrin signaling, myocardial infarction protection by inhibiting PI3K/AKT/mTOR, and other conditions. Its context-dependent roles, e.g., pro-fibrotic in lungs vs. protective in heart, and involvement in key signaling pathways highlight its potential as a therapeutic target, though challenges like inhibitor specificity remain.

University of Warwick researchers have built a new diamond-based magnetic field sensor that could be used to better find tumours through tracing magnetic fluid injected in the body. 

In the era of global climate change, personal thermoregulation has become critical to addressing the growing demands for thermoadaptability, comfort, health, and work efficiency in dynamic environments. Here, we introduce an innovative three-dimensional (3D) self-folding knitted fabric that achieves dual thermal regulation modes through architectural reconfiguration. In the warming mode, the fabric maintains its natural 3D structure, trapping still air with extremely low thermal conductivity to provide high thermal resistance (0.06 m² K W⁻¹), effectively minimizing heat loss. In the cooling mode, the fabric transitions to a 2D flat state via stretching, with titanium dioxide (TiO₂) and polydimethylsiloxane (PDMS) coatings that enhance solar reflectivity (89.5%) and infrared emissivity (93.5%), achieving a cooling effect of 4.3 °C under sunlight. The fabric demonstrates exceptional durability and washability, enduring over 1000 folding cycles, and is manufactured using scalable and cost-effective knitting techniques. Beyond thermoregulation, it exhibits excellent breathability, sweat management, and flexibility, ensuring wear comfort and tactile feel under diverse conditions. This study presents an innovative solution for next-generation adaptive textiles, addressing the limitations of static thermal fabrics and advancing personal thermal management with wide applications for wearable technology, extreme environments, and sustainable fashion.